| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $42.7M | — | +16.0% |
| SG&A Expense | $11.5M | — | +24.6% |
| Operating Income | -$54.1M | — | -17.7% |
| Net Income | -$49.0M | — | -20.1% |
| EPS (Basic) | -$0.46 | — | -7.0% |
| EPS (Diluted) | -$0.46 | — | -7.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $33.2M | -45.7% | -33.5% |
| Current Assets | $509.8M | -6.2% | +15.0% |
| Total Assets | $518.5M | -6.2% | +14.1% |
| Current Liabilities | $22.5M | -17.6% | +6.8% |
| Total Liabilities | $25.3M | -16.6% | +2.6% |
| Stockholders' Equity | $493.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$42.5M | — | -12.4% |
| Capital Expenditures | $260K | — | +490.9% |
| Investing Cash Flow | $2.4M | — | -94.5% |
| Financing Cash Flow | $12.2M | — | +447.6% |
| Free Cash Flow | -$42.8M | — | -12.9% |
| +14.8% |